Story
Novo Nordisk Seeks Approval for Oral Wegovy in China, Intensifying Rivalry with Eli Lilly

Novo Nordisk said on Thursday its application to sell an oral version of its weight-loss drug Wegovy has been accepted by China’s drug regulator. The move signals a new front in the company's competition with U.S. rival Eli Lilly for dominance in the world's second-largest pharmaceutical market.
A New Front in the GLP-1 Race
The acceptance of the application paves the way for a potential launch of a pill-based version of the popular GLP-1 drug, which works by mimicking a gut hormone to suppress appetite. Both Novo Nordisk and Eli Lilly are betting that oral medications will attract a wider patient base than the current once-weekly injections, particularly among those hesitant to use needles.
This development follows a similar move by Eli Lilly, which, according to a company statement in March, submitted its marketing application for a once-daily oral GLP-1 drug, orforglipron, to Chinese regulators at the end of 2025. An executive told Reuters that Lilly's drug could launch in China as soon as this year.
Market Projections and Drivers
The competition for weight-management therapies in China is intensifying amid significant market potential. The country's National Health Commission has projected that the rate of overweight or obese people could exceed 65% by 2030.
AdAccording to recent analysis from J.P. Morgan’s head of China healthcare research, Yang Huang, sales of GLP-1 therapies for weight management in China could surge to 30 billion yuan ($4.46 billion) within the next five to seven years. This represents a substantial increase from the current estimated market size of 3 billion to 4 billion yuan.
Global Competitive Landscape
While Eli Lilly appears to have a head start in the race for an oral treatment in China, Novo Nordisk has already made progress elsewhere. The Danish firm has launched its Wegovy pill in the United States this year following early approvals in the U.S. and Britain.
Eli Lilly secured U.S. approval for orforglipron in April. The two pharmaceutical giants, along with others like Pfizer and local Chinese firm Innovent Biologics, are all vying for market share with their respective GLP-1 treatments.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.